vildagliptin + placebo of vildagliptin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Congestive Heart Failure

Conditions

Congestive Heart Failure, Type II Diabetes Mellitus

Trial Timeline

May 1, 2009 → Aug 1, 2012

NCT ID

NCT00894868

About vildagliptin + placebo of vildagliptin

vildagliptin + placebo of vildagliptin is a approved stage product being developed by Novartis for Congestive Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT00894868. Target conditions include Congestive Heart Failure, Type II Diabetes Mellitus.

What happened to similar drugs?

5 of 20 similar drugs in Congestive Heart Failure were approved

Approved (5) Terminated (5) Active (11)

✅Dapagliflozin + PlaceboAstraZenecaApproved

✅Low Dose Bisoprolol + High Dose BisoprololMerckApproved

✅Angiotensin-Converting Enzyme Inhibitor + Angiotensin II Type 1 Receptor Blocker + sacubitril/valsartanNovartisApproved

✅atorvastatin + placeboPfizerApproved

✅EplerenonePfizerApproved

🔄Seloken ZOK/Toprol-XL + Seloken ZOK/Toprol-XL + PlaceboAstraZenecaPhase 3

🔄Candesartan + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00894868	Approved	Completed	May 1, 2009	Aug 1, 2012	Congestive Heart Failure

Competing Products

20 competing products in Congestive Heart Failure

See all competitors

Product	Company	Stage	Hype Score
IV diuretic	Nuwellis	Pre-clinical	16
Carperitide + Placebo	Daiichi Sankyo	Phase 2	35
Seloken ZOK/Toprol-XL + Seloken ZOK/Toprol-XL + Placebo	AstraZeneca	Phase 3	40
Candesartan + Placebo	AstraZeneca	Phase 3	40
AC2592 + placebo	AstraZeneca	Phase 2	35
Dapagliflozin + Placebo	AstraZeneca	Approved	43
Enoximone + Metoprolol succinate + Placebo to match enoximone + Placebo to match metoprolol succinate	AstraZeneca	Phase 3	32
Candesartan + Placebo	AstraZeneca	Phase 3	40
Candesartan + Placebo	AstraZeneca	Phase 3	40
Rosuvastatin	AstraZeneca	Phase 3	40
KW-3902IV	Merck	Phase 2	35
rolofylline + Comparator: Placebo (unspecified)	Merck	Phase 3	40
KW-3902IV	Merck	Phase 2	35
Sitagliptin	Merck	Phase 1	29
Low Dose Bisoprolol + High Dose Bisoprolol	Merck	Approved	43
rolofyline + Comparator Placebo (unspecified)	Merck	Phase 2	35
rolofylline + Comparator: Placebo (unspecified)	Merck	Phase 3	40
rolofylline + Comparator: Placebo (unspecified)	Merck	Phase 3	40
Relaxin + Placebo	Novartis	Phase 2/3	38
Relaxin	Novartis	Phase 2	35